Ken Griffin Red Hill Biopharma Ltd. Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.65 - $3.12 $74,330 - $140,552	-45,049 Reduced 43.84%	57,713 $145,000
Q4 2021 Feb 14, 2022	BUY	$2.31 - $5.85 $145,148 - $367,584	62,835 Added 157.37%	102,762 $265,000
Q3 2021 Nov 15, 2021	BUY	$4.55 - $10.36 $74,943 - $170,639	16,471 Added 70.22%	39,927 $183,000
Q3 2020 Nov 16, 2020	BUY	$6.34 - $10.83 $28,650 - $48,940	4,519 Added 23.86%	23,456 $240,000
Q1 2020 May 15, 2020	BUY	$3.51 - $6.17 $23,387 - $41,110	6,663 Added 54.29%	18,937 $86,000
Q4 2019 Feb 14, 2020	SELL	$5.76 - $7.35 $33,949 - $43,320	-5,894 Reduced 32.44%	12,274 $75,000
Q4 2018 Feb 14, 2019	SELL	$5.18 - $9.35 $51,033 - $92,116	-9,852 Reduced 35.16%	18,168 $100,000
Q1 2018 May 11, 2018	SELL	$4.96 - $6.84 $25,484 - $35,143	-5,138 Reduced 15.5%	28,020 $145,000
Q4 2017 Feb 09, 2018	BUY	$4.58 - $10.81 $151,863 - $358,437	33,158	33,158 $170,000

40.4K

Ticker RDHL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 63,823,500
Market Cap $465M
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.